PMID- 27739368
OWN - NLM
STAT- MEDLINE
DCOM- 20170208
LR  - 20211204
IS  - 1875-533X (Electronic)
IS  - 0929-8673 (Linking)
VI  - 23
IP  - 37
DP  - 2016
TI  - Current Use of mTOR Inhibitors for the Treatment of Subependymal Giant Cell 
      Astrocytomas and Epilepsy in Patients with TSC.
PG  - 4260-4269
AB  - The serine/threonine kinase mechanistic target of rapamycin (mTOR) is an 
      important sensor of the cellular energy condition which, at the same time, 
      represents a kind of master switch between anabolic and catabolic cellular 
      processes. Tuberous sclerosis complex (TSC) is a genetic disease which is 
      considered to be a prototype of a dysregulated mTOR signaling pathway. The 
      dysregulated mTOR pathway in TSC leads to characteristic structural and 
      physiologic abnormalities in multiple organs. In this review we focus on the 
      pharmacological properties of mTOR inhibitors and clinical investigations of mTOR 
      inhibitors for two important neurological TSC manifestations: subependymal giant 
      cell astrocytomas (SEGAs) and epilepsy. Moreover, we present a safety profile of 
      those agents and their current role in clinical practice.
FAU - Jancic, Jasna
AU  - Jancic J
FAU - Duric, Vesna
AU  - Duric V
FAU - Ivancevic, Nikola
AU  - Ivancevic N
FAU - Nikolic, Blazo
AU  - Nikolic B
FAU - van den Anker, John N
AU  - van den Anker JN
FAU - Samardzic, Janko
AU  - Samardzic J
AD  - Institute of Pharmacology, Clinical Pharmacology and Toxicology, Medical Faculty, 
      University of Belgrade, Dr Subotica 1, 11129 Belgrade, Serbia.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United Arab Emirates
TA  - Curr Med Chem
JT  - Current medicinal chemistry
JID - 9440157
RN  - 0 (Immunosuppressive Agents)
RN  - 9HW64Q8G6G (Everolimus)
RN  - EC 2.7.1.1 (MTOR protein, human)
RN  - EC 2.7.11.1 (TOR Serine-Threonine Kinases)
SB  - IM
MH  - Astrocytoma/complications/*drug therapy
MH  - Clinical Trials as Topic
MH  - Epilepsy/complications/*drug therapy
MH  - Everolimus/therapeutic use
MH  - Humans
MH  - Immunosuppressive Agents/*therapeutic use
MH  - TOR Serine-Threonine Kinases/antagonists & inhibitors/*metabolism
MH  - Tuberous Sclerosis/complications/genetics/*pathology
EDAT- 2016/10/16 06:00
MHDA- 2017/02/09 06:00
CRDT- 2016/10/15 06:00
PHST- 2016/03/25 00:00 [received]
PHST- 2016/05/27 00:00 [revised]
PHST- 2016/10/06 00:00 [accepted]
PHST- 2016/10/16 06:00 [pubmed]
PHST- 2017/02/09 06:00 [medline]
PHST- 2016/10/15 06:00 [entrez]
AID - CMC-EPUB-78885 [pii]
AID - 10.2174/0929867323666161013091144 [doi]
PST - ppublish
SO  - Curr Med Chem. 2016;23(37):4260-4269. doi: 10.2174/0929867323666161013091144.